Work

Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma

Year: 2025

Type: article

Abstract: Introduction: We report a case in which enfortumab vedotin (EV) therapy was administered as a third-line treatment for locally advanced bladder cancer (bc), enabling successful radical resection. Case Presentation: This report describes the case of a 69-year-old male patient with locally advanced bc and pelvic lymph node (LN) metastases. After the failure of first-line chemotherapy and second-line immunotherapy, the patient received EV as third-line treatment. EV therapy resulted in significant tumor reduction, enabling successful radical cystectomy and lymph node dissection (LND). The patient remained recurrence-free for 22 months post-surgery. Conclusion: EV therapy suggests that it is a promising avenue for further exploration, potentially redefining the therapeutic landscape of historically challenging cases.

Source: IJU Case Reports

DOI: 10.1002/iju5.70019

Authors: Keita Minami, Rei Narimatsu, Hajime Sasaki, Tatsu Tanabe, Hiroshi Tanaka

Institution: Sapporo City General Hospital

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,960